RXRX News and Press, Recursion Pharmaceuticals Inc.

2025-03-12 17:49:33 ET Summary Recursion Pharmaceuticals is a pioneer in AI-powered drug discovery but faces challenges in monetizing its innovations and aligning management's vision with sustainable revenue paths. The company's partnerships with big pharma and its proprietary AI ...

2025-03-10 11:47:48 ET Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage biotech company, which is a pioneer in using artificial intelligence (AI) in drug discovery, didn't announce any news that would ca...

2025-03-08 10:02:00 ET The artificial intelligence (AI) industry has been on a tear in the past two years, and judging by analyst estimates, it's just the beginning. AI-related sales will continue to soar in the coming years, so naturally, investors want to cash in by investing in those com...

2025-03-07 08:30:00 ET Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (NASDAQ: RXRX) . The company has emerged as a leader in drug discovery, enabled by artificial intelligen...

2025-03-07 04:55:00 ET It's typically not too difficult to find a company that should perform well for the next couple of years. Two years isn't very long, after all, and the stock market's dynamics tend to dictate performance more. Identifying a stock that's likely to lead a marketwide...

2025-03-06 05:03:00 ET Machine-learning techniques keep improving efficiency in one industry after another. One corner of the economy where investors expect another big leap forward is the world of drug development. For every commercial-stage drug out there that generates millions and s...

2025-02-28 13:17:35 ET More on Recursion Pharmaceuticals Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Of...

2025-02-28 13:16:57 ET Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Conference Call February 28, 2025 08:30 AM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Lina Nilsson - Senior Vice President & Head of Platform B...

2025-02-28 06:32:37 ET More on Recursion Pharmaceuticals Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off Recursion Pharmaceuticals: Betting Big On AI Seeking Alpha...

National American University Holdings Inc (NAUH) is expected to report for Q2 2025 Chart Industries Inc. (GTLS) is expected to report $3.19 for Q4 2024 Rapid Micro Biosystems Inc. (RPID) is expected to report $-0.24 for Q4 2024 Basf SE ADR (BASFY) is expected to report $0.11 for Q4 20...